Hudson Bay Capital Management’s Estrella Immunopharma ESLA Stock Holding History

Hudson Bay Capital Management’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-175,000	Closed	-$1.76M	–	1028
2022 Q3	$1.76M	Hold	175,000	–	–	0.02%	765
2022 Q2	$1.75M	Hold	175,000	–	–	0.01%	831
2022 Q1	$1.75M	Hold	175,000	–	–	0.02%	732
2021 Q4	$1.73M	Hold	175,000	–	–	0.02%	717
2021 Q3	$1.73M	Buy	+175,000	New	+$1.72M	0.02%	663

Other funds holding ESLA

KIM

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

HHGC

Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Hudson Bay Capital Management's ESLA Position: Q4 2022 in Review

Hudson Bay Capital Management sold out of Estrella Immunopharma (ESLA) in Q4 2022, closing a stake of 175,000 shares — an estimated $1.76M sold.

Hudson Bay Capital Management first reported a position in ESLA in Q3 2021 and held it in 5 quarters. The position peaked at $1.76M in Q3 2022. 13 funds tracked by Wall St. Rank hold ESLA as of Q4 2022.

Hudson Bay Capital Management reported no remaining Estrella Immunopharma position as of Q4 2022 after selling out during the quarter.
Hudson Bay Capital Management sold 175,000 Estrella Immunopharma shares in Q4 2022, an estimated $1.76M.
Hudson Bay Capital Management first reported a position in Estrella Immunopharma in Q3 2021 and held it in 5 quarters.
Hudson Bay Capital Management's Estrella Immunopharma position peaked at $1.76M in Q3 2022.
13 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q4 2022.

Based on Hudson Bay Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.